A stakeholder-centered development approach for large-volume drug delivery solutions

Larger subcutaneous injections are becoming more prominent due to recent advances in formulation development and new therapeutic areas. Therefore, novel large -volume autoinjectors need to be developed to fulfill this new demand. As the interplay of device and container is crucial for a safe and reliable drug administration, a co-development between container and device manufacturers is a meaningful way to understand and address all relevant stakeholder needs.

In this Pharmaversity® session, experts from SCHOTT Pharma and Ypsomed will provide an insight into how pharmaceutical requirements, user needs, processability, and business requirements have guided the co-development of YpsoMate® 5.5 autoinjector and syriQ BioPure® 5.5ml prefillable glass syringe.